...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Short interest for the past year...

An inconsequential number of shares.  Microscopic compared to many other biotechs with phase 2/3 clinical trials.

 

 

Share
New Message
Please login to post a reply